BioCardia/ US09060U6064 /
| 9/26/2024 9:59:52 PM | Chg. +0.18 | Volume | Bid- | Ask- | High | Low |
|---|---|---|---|---|---|---|
| 2.76USD | +6.98% | 177 Turnover: 490.53 |
-Bid Size: - | -Ask Size: - | 2.79 | 2.76 |
GlobeNewswire
8/30
BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasda...
GlobeNewswire
8/29
BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family
GlobeNewswire
8/21
FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analys...
GlobeNewswire
8/7
BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024
GlobeNewswire
7/30
BioCardia Submits for FDA Approval of Morph® DNA™ Steerable Introducer Product Family
GlobeNewswire
7/25
Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of ...
GlobeNewswire
7/17
BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter ...
GlobeNewswire
7/8
CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes™ for the Treatm...
GlobeNewswire
6/7
BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to ...
GlobeNewswire
5/9
BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024
GlobeNewswire
5/1
BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in...
GlobeNewswire
4/25
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Isch...
GlobeNewswire
3/27
BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
GlobeNewswire
3/20
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024
GlobeNewswire
3/12
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart ...
GlobeNewswire
3/4
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial,...
GlobeNewswire
2/8
BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved ...
GlobeNewswire
1/3
BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Share...
GlobeNewswire
12/19/2023
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchym...
